Note: As FDA indexes SPL, only VA MED-RT and NDF-RT Classifications that the FDA considers scientifically valid and clinically meaningful are used. Therefore, the drug classes that are available for a DailyMed query represent a subset of all VA MED-RT and NDF-RT classifications.
To find drugs that belong to a specific drug class, type in the drug class in the search box or select from the list of drug classes.
- Bacterial Neurotoxin Neutralization [MoA]
- Barbiturate [EPC]
- BCL-2 Inhibitor [EPC]
- Benzodiazepine Antagonist [EPC]
- Benzodiazepine [EPC]
- Benzothiazole [EPC]
- Benzylamine Antifungal [EPC]
- beta2-Adrenergic Agonist [EPC]
- beta3-Adrenergic Agonist [EPC]
- beta-Adrenergic Agonist [EPC]
- beta-Adrenergic Blocker [EPC]
- beta Lactamase Inhibitor [EPC]
- beta Lactamase Inhibitors [MoA]
- Biguanide [EPC]
- Bile-acid Binding Activity [MoA]
- Bile Acid [EPC]
- Bile Acid Sequestrant [EPC]
- Bismuth [EPC]
- Bispecific CD19-directed CD3-directed T Cell Engager [EPC]
- Bisphosphonate [EPC]
- Blood Coagulation Factor [EPC]
- Blood Viscosity Reducer [EPC]
- B Lymphocyte Stimulator-directed Antibody Interactions [MoA]
- B Lymphocyte Stimulator-specific Inhibitor [EPC]
- Bradykinin B2 Receptor Antagonist [EPC]
- Bradykinin B2 Receptor Antagonists [MoA]
- Breast Cancer Resistance Protein Inhibitors [MoA]
- Calcineurin Inhibitor Immunosuppressant [EPC]
- Calcineurin Inhibitors [MoA]
- Calcitonin [EPC]
- Calcium Channel Antagonists [MoA]
- Calcium Channel Blocker [EPC]
- Calcium Chelating Activity [MoA]
- Calcium [EPC]
- Calcium-sensing Receptor Agonist [EPC]
- Calculi Dissolution Agent [EPC]
- Cannabinoid [EPC]
- Carbamoyl Phosphate Synthetase 1 Activator [EPC]
- Carbamoyl Phosphate Synthetase 1 Activators [MoA]
- Carbonic Anhydrase Inhibitor [EPC]
- Carbonic Anhydrase Inhibitors [MoA]
- Carboxypeptidase [EPC]
- Cardiac Glycoside [EPC]
- Cardiac Rhythm Alteration [PE]
- Carnitine Analog [EPC]
- Catecholamine-depleting Sympatholytic [EPC]
- Catecholamine [EPC]
- Catecholamine Synthesis Inhibitor [EPC]
- Catecholamine Synthesis Inhibitors [MoA]
- Catechol-O-Methyltransferase Inhibitor [EPC]
- Catechol O-Methyltransferase Inhibitors [MoA]
- CCR5 Co-receptor Antagonist [EPC]
- CD19-directed Antibody Interactions [MoA]
- CD20-directed Antibody Interactions [MoA]
- CD20-directed Cytolytic Antibody [EPC]
- CD20-directed Radiotherapeutic Antibody [EPC]
- CD22-directed Antibody Interactions [MoA]
- CD22-directed Immunoconjugate [EPC]
- CD30-directed Antibody Interactions [MoA]
- CD30-directed Immunoconjugate [EPC]
- CD33-directed Antibody Interactions [MoA]
- CD33-directed Immunoconjugate [EPC]
- CD38-directed Antibody Interactions [MoA]
- CD38-directed Cytolytic Antibody [EPC]
- CD3-directed Antibody Interactions [MoA]
- CD3 Receptor Agonists [MoA]
- CD52-directed Antibody Interactions [MoA]
- CD52-directed Cytolytic Antibody [EPC]
- CD80-directed Antibody Interactions [MoA]
- CD86-directed Antibody Interactions [MoA]
- Cell Death Inducer [EPC]
- Cell-mediated Immunity [PE]
- Central alpha-2 Adrenergic Agonist [EPC]
- Centrally-mediated Muscle Relaxation [PE]
- Central Nervous System Depressant [EPC]
- Central Nervous System Depression [PE]
- Central Nervous System Stimulant [EPC]
- Central Nervous System Stimulation [PE]
- Cephalosporin Antibacterial [EPC]
- Chelating Activity [MoA]
- Chemokine Co-receptor 5 Antagonists [MoA]
- Chloride Channel Activation Potentiators [MoA]
- Chloride Channel Activator [EPC]
- Chloride Channel Activators [MoA]
- Cholecystokinin Analog [EPC]
- Cholinergic Agonists [MoA]
- Cholinergic Antagonists [MoA]
- Cholinergic Muscarinic Agonist [EPC]
- Cholinergic Muscarinic Agonists [MoA]
- Cholinergic Muscarinic Antagonist [EPC]
- Cholinergic Muscarinic Antagonists [MoA]
- Cholinergic Nicotinic Agonist [EPC]
- Cholinergic Receptor Agonist [EPC]
- Cholinesterase Inhibitor [EPC]
- Cholinesterase Inhibitors [MoA]
- Cholinesterase Reactivator [EPC]
- Cholinesterase Reactivators [MoA]
- Collagenases [Chemical/Ingredient]
- Collagen-specific Enzyme [EPC]
- Competitive Opioid Antagonists [MoA]
- Complement Inhibitor [EPC]
- Complement Inhibitors [MoA]
- Contrast Agent for Ultrasound Imaging [EPC]
- Copper Absorption Inhibitor [EPC]
- Copper-containing Intrauterine Device [EPC]
- Corticosteroid [EPC]
- Corticosteroid Hormone Receptor Agonists [MoA]
- CTLA-4-directed Antibody Interactions [MoA]
- CTLA-4-directed Blocking Antibody [EPC]
- Cyclooxygenase Inhibitor [EPC]
- Cyclooxygenase Inhibitors [MoA]
- Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC]
- Cystine Depleting Agent [EPC]
- Cystine Disulfide Reduction [MoA]
- Cytochrome P450 17A1 Inhibitor [EPC]
- Cytochrome P450 17A1 Inhibitors [MoA]
- Cytochrome P450 1A2 Inducers [MoA]
- Cytochrome P450 1A2 Inhibitors [MoA]
- Cytochrome P450 1A Inducers [MoA]
- Cytochrome P450 2B6 Inducers [MoA]
- Cytochrome P450 2B6 Inhibitors [MoA]
- Cytochrome P450 2C19 Inducers [MoA]
- Cytochrome P450 2C19 Inhibitors [MoA]
- Cytochrome P450 2C8 Inducers [MoA]
- Cytochrome P450 2C8 Inhibitors [MoA]
- Cytochrome P450 2C9 Inducers [MoA]
- Cytochrome P450 2C9 Inhibitors [MoA]
- Cytochrome P450 2D6 Inducers [MoA]
- Cytochrome P450 2D6 Inhibitor [EPC]
- Cytochrome P450 2D6 Inhibitors [MoA]
- Cytochrome P450 3A4 Inducers [MoA]
- Cytochrome P450 3A4 Inhibitors [MoA]
- Cytochrome P450 3A5 Inhibitors [MoA]
- Cytochrome P450 3A Inducers [MoA]
- Cytochrome P450 3A Inhibitor [EPC]
- Cytochrome P450 3A Inhibitors [MoA]
- Cytolytic Agent [EPC]
- Cytomegalovirus DNA Terminase Complex Inhibitor [EPC]
- Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor [EPC]
- Cytoprotective Agent [EPC]